Sung Wei-Ting, Sakai Kunihiro, Etou Haruka, Yamamichi Rikiko, Yoneda Tomoko, Matsuura Toshiaki, Maruyama Tomoyoshi, Nishi Daisuke
Department of Obstetrics and Gynecology, Saiseikai Fukuoka General Hospital, 1-3-46, Tenjin, Chuo-ku, Fukuoka, 810-0001 Japan.
Department of Gynecology and Obstetrics, Faculty of Medicine, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.
Int Cancer Conf J. 2023 Jul 5;12(4):305-310. doi: 10.1007/s13691-023-00621-x. eCollection 2023 Oct.
We present the case of a 39-year-old woman with platinum-resistant ovarian cancer who was treated with pembrolizumab. After five cycles of pembrolizumab treatment, she suddenly developed cardiac tamponade with a pleural effusion. The malignant pericardial and pleural effusion had increased, while the other malignant lesions had diminished in size. After pericardial and pleural drainage, no re-accumulation occurred. Pembrolizumab was continued and the patient did not have tumor progression for > 20 months. In some patients with pembrolizumab-induced cardiac tamponade, continuation of pembrolizumab treatment may be possible if other lesions decrease in size and the pericardial effusion can be controlled after drainage.
我们报告了一例39岁铂耐药卵巢癌女性患者，其接受了帕博利珠单抗治疗。在接受五个周期的帕博利珠单抗治疗后，她突然出现心包填塞并伴有胸腔积液。恶性心包积液和胸腔积液增多，而其他恶性病变体积缩小。心包和胸腔引流后，积液未再积聚。继续使用帕博利珠单抗治疗，患者超过20个月未出现肿瘤进展。在一些帕博利珠单抗引起心包填塞的患者中，如果其他病变体积缩小且心包积液在引流后能够得到控制，可能可以继续使用帕博利珠单抗治疗。
